Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SQ 3370 (Primary)
  • Indications Advanced breast cancer; Brain metastases; Carcinoma; Fallopian tube cancer; Gynaecological cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Shasqi

Most Recent Events

  • 16 Jun 2025 According to a Shasqi media release, the company announced the publication of a manuscript detailing the preclinical development and translation of SQ3370 to a first-in-human dose-escalation clinical trial in patients with advanced solid tumor,in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
  • 04 Jun 2024 Interim analysis (n=14) showing clinical proof of concept with SQ3370 in patients with advanced STS presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 Oct 2023 Results (n=38) of phase 1 presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top